Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2013
At a glance
- Drugs Selumetinib (Primary) ; Temsirolimus (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jan 2012 Actual patient number (4) added as reported by ClinicalTrials.gov.
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.